- Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists
-
The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.
- Durner, Anna,Koufaki, Maria,Kritsi, Eftichia,Nicke, Annette,Papakostas, Alexios,T. Pournara, Dimitra,Zoumpoulakis, Panagiotis
-
supporting information
p. 2530 - 2543
(2020/10/19)
-
- FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
-
Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1. Further provided are a pharmaceutical composition and a method of treating a disease regulated by ASK1 comprising administering the compounds or pharmaceutical composition thereof.
- -
-
Paragraph 00176; 00212
(2019/03/05)
-
- One-pot synthesis of novel 3,5-disubstituted-1,2,4-oxadiazoles from indazole carboxylic acid esters and amidoximes
-
An efficient and high-yielding one-pot synthesis of 3,5-disubstituted-1,2, 4-oxadiazoles from indazole carboxylic acid methyl esters and amidoximes is described. In this study a series of novel 3,5-disubstituted-1,2,4-oxadiazoles (3a-d), (4a-d), (5a-d), (6a-d), (7a-d) were synthesized using amidoximes 2a-d and indazole carboxylic acid esters (3-6).
- Swamy, Udutha Kumara,Mohan, H. Rama,Prasad, U. Viplava,Suresh,Kumar, T. Laxmi
-
p. 1921 - 1930
(2014/06/09)
-
- GLUTAMATE DERIVATIVES OR SALTS THEREOF
-
Compounds having an excellent CaSR agonist activity are in demand. The invention provides glutamate derivatives or salts thereof, pharmaceutical compositions comprising the glutamate derivatives, preventive or therapeutic agents for diarrhea, hyperparathyroidism or peptic ulcer.
- -
-
Paragraph 0150
(2013/03/26)
-
- PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY
-
A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.
- -
-
Paragraph 0123
(2013/03/26)
-
- SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS
-
The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
- -
-
Page/Page column 73
(2013/09/26)
-
- RING-FUSED COMPOUND
-
The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.
- -
-
Paragraph 0523-0524
(2014/01/07)
-
- HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
-
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
- -
-
Page/Page column 83
(2012/11/08)
-
- BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE
-
Disclosed are compounds, compositions and methods for treatingFlaviviridae family virus infections.
- -
-
Page/Page column 181
(2008/06/13)
-
- BICYCLIC DERIVATIVES AS PPAR MODULATORS
-
The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.
- -
-
Page/Page column 93
(2008/06/13)
-
- Methods of making 2,6-diaryl piperidine derivatives
-
Methods for preparing 2,6-diaryl piperidine derivatives are described. More particularly, 2,6-diaryl piperidines having formula 1-4 are prepared by cyclocondensation of an aryl or heteroaryl aldehyde with 1,3-acetonedicarboxylic acid.
- -
-
-
- Thromboxane A2 synthetase inhibitors with histamine H1-blocking activity: Synthesis and evaluation of a new series of indole derivatives
-
A novel series of N-substituted 3-(1H-imidazol-1-ylmethyl)indole carboxylic acid derivatives were prepared and evaluated for thromboxane A2 (TXA2) synthetase-inhibitory and histaminergic H1-blocking activity. Among the compounds synthesized, indole-6-carboxylic acid derivatives showed higher activities than the other positional isomers of carboxylic acid. 1-[3-(4- Benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6- carboxylic acid (12) had the strongest thromboxane synthetase inhibitory activity (IC50 = 5 x 10-8 M) and H1-blocking activity (IC50 = 8 x 10- 9 M).
- Kamiya,Matsui,Shirahase,Nakamura,Wada,Kanda,Shimaji,Kakeya
-
p. 1692 - 1695
(2007/10/03)
-
- ALKALINE C-S BOND CLEAVAGE OF SOME ARYLTHIOMETHYL BENZOATES
-
Methyl and ethyl--3-nitrobenzoates and the corresponding non-nitro derivatives have been synthesized and their structures proven.The action of 5percent sodium hydroxide solution on these esters gave the corresponding diaryl disulfides besides 3-nitro-4-methylbenzoic acid or 4-methylbenzoic acid. Key words: Arylthiomethyl benzoates; C-S bond fission and mass spectra.
- El-Zahraa Fatma,El-Hegazy, M.,El-Bardan, Ali A.,Hamed, Ezzat A.
-
p. 113 - 122
(2007/10/02)
-
- OXIDATION BY THE SALTS OF METALS. IV. OXIDATIVE HALOGENATION OF TOLUENE AND PARA-SUBSTITUTED TOLUENES WITH ELECTRON-WITHDRAWING GROUPS PROMOTED BY CERIUM(IV) SALTS IN AQEOUS SOLUTIONS OF TRIFLUOROACETIC ACID
-
The oxidation of toluene and para-substituted toluenes with electron-withdrawing groups (para-toluic acid, methyl para-toluate, and para-nitrotoluene) by ammonium cerium(IV) nitrate and ammonium cerium(IV) sulfate was investigated in aqueous solutions of trifluoroacetic acid in the presence of alkali-metal chlorides and bromides.The rate and selectivity of oxidative halogenation in the side chain and/or aromatic ring under the investigated conditions depends strongly both on the nature of the substrate and the halide ion and on the reaction conditions and the ligand environment of the cerium(IV) atom.The oxidation of nitrotoluene takes place only in the presence of the bromide-containing systems and leads to the production of 4-nitrobenzyl bromide.For the other substrates halogenation in the aromatic ring can be realized with yields close to quantitative with ammonium cerium(IV) nitrate as oxidizing agent in concentrated aqueous solutions of trifluoroacetic acid (10 vol.percent of water).It was shown that the halogenating agents in this case are mainly the products from oxidation of the halide ions by the nitronium ions formed in the strongly acidic medium from the nitrate ions contained in the ammonium cerium(IV) nitrate.Bromination of the substituted toluenes in the presence of ammonium cerium(IV) sulfate and in the ammonium cerium(IV) nitrate-alkali-metal bromide systems with more than 10 vol.percent of water takes mainly in the side chain and can be used as a method for the production of 4-substituted benzyl halides with preparative yields.The effect of the composition of the solvent and the ratio of the oxidizing agent and alkali-metal halide on the rate and selectivity of oxidative bromination was studied.Possible reaction mechanisms are discussed.
- Makhon'kov, D.I.,Cheprakov, A.V.,Rodkin, M.A.,Mil'chenko, A.Yu.,Beletskaya, I.P.
-
-